LP
FULC icon

LMR Partners’s Fulcrum Therapeutics FULC Stock Holding History

LMR Partners’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-42,100
Closed -$150K – 1343
2024
Q3 		$150K Buy
+42,100
New +$312K ﹤0.01% 1023

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

LMR Partners's FULC Position: Q1 2026 in Review

LMR Partners held its Fulcrum Therapeutics (FULC) position steady in Q1 2026 at 30,000 shares worth $230K. The position accounts for ﹤0.01% of the portfolio, ranked #1178.

LMR Partners first reported a position in FULC in Q3 2021 and has held it in 7 quarters since. The position peaked at $846K in Q3 2021. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • LMR Partners held 30,000 shares of Fulcrum Therapeutics worth $230K as of Q1 2026.
  • LMR Partners left its Fulcrum Therapeutics share count unchanged in Q1 2026.
  • Fulcrum Therapeutics made up ﹤0.01% of LMR Partners's portfolio in Q1 2026, its #1178 holding.
  • LMR Partners first reported a position in Fulcrum Therapeutics in Q3 2021 and has held it in 7 quarters since.
  • LMR Partners's Fulcrum Therapeutics position peaked at $846K in Q3 2021.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.